Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

The authors describe the differences between patients with essential thrombocythemia who have either JAK2- or CALR-mutations. Mutations in JAK2 or CALR are present in about 50% and 25% of patients with essential thrombocythemia, respectively, and these mutations are thought to drive myeloproliferative neoplasms (MPNs). CALR and JAK2 mutations are mutually exclusive in MPNs.

Ann Lab Med